Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients

Clinical Nephrology

Volumn 71, Issue 2, 2009, Pages 125-129

  Grimmelt, A C ^a   Cohen, C D ^a   Fehr, T ^a   Serra, A L ^a   Wüthrich, Rudolf P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anemia; Chronic kidney disease; Ferric carboxymaltose; Iron deficiency; Renal transplantation

Indexed keywords

ANTIANEMIC AGENT; FERINJECT; FERRIC CARBOXYMALTOSE; HEMOGLOBIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FERRIC ION; MALTOSE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INFUSION RATE; IRON DEFICIENCY; KIDNEY TRANSPLANTATION; LABORATORY TEST; MALE; METALLIC TASTE; QUESTIONNAIRE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; VITAL SIGN; CHRONIC KIDNEY FAILURE; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; NONPARAMETRIC TEST; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MALTOSE; PROSPECTIVE STUDIES; QUESTIONNAIRES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 64549090727     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71125     Document Type: Article

References (25)

1. Afzali B, Al-Khoury S, Shah N, Mikhail A, Covic A, Goldsmith D. Anemia after renal transplantation. Am J Kidney Dis. 2006; 48: 519-536.
2. Anirban G, Kohli HS, Jha V, Gupta KL, Sakhuja V. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail. 2008; 30: 629-638.
3. Awobusuyi JO, Mapayi FA, Adedolapo A. Blood loss during vascular access cannulation: quantification using the weighed gauze and drape method. Hemodial Int. 2008; 12: 90-93.
4. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005; 20: 1443-1449.
5. Beshara S, Sorensen J, Lubberink M et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol. 2003; 120: 853-859.
6. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008; 101: 67-73.
7. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001; 38: 988-991.
8. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21: 378-382.
9. Gordon S. Iron carboxymaltose, a new intravenous iron agent for iron deficiency in heavy uterine bleeding. Obstet Gynecol. 2007; (Suppl. 4): 1S-127S.
10. Hollands JM, Foote EF, Rodriguez A, Rothschild J, Young S. Safety of high-dose iron sucrose infusion in hospitalized patients with chronic kidney disease. Am J Health Syst Pharm. 2006; 63: 731-734.
11. Joist H, Brennan DC, Coyne DW. Anemia in the kidney-transplant patient. Adv Chron Kidney Dis. 2006; 13: 4-10.
12. Kooistra MP, Marx JJ. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial Transplant. 1998; 13: 2578-2582.
13. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant. 1998; 13: 82-88.
14. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008; 103: 1182-1192.
15. Li H,Wang SX. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int. 2008; 28: 149-154.
16. Locatelli AP, Bárány P. European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; (19 Suppl. 2): ii1-ii47.
17. Mircescu G, Garneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant. 2006; 21: 120-124.
18. Qunibi W, Quinn D, Benjamin J. Safety and tolerability profile of ferric carboxymaltose (FCM), a new high-dose intravenous iron, across ten multicenter clinical trials. J Am Soc Nephrol. 2007; 18: 813A (abstract).
19. Qunibi W, Martinez C, Smith M, Benjamin J, Dinh Q. Efficacy and safety of i.v. ferric carboxymaltose (FCM) compared to oral iron in anemic patients with nondialysis-dependent CKD. Nephrol Dial Transplant Plus. 2008; 1 (Suppl. 2): ii217 (abstract).
20. Rigatto C. Anemia, renal transplantation, and the anemia paradox. Semin Nephrol. 2006; 26: 307-312.
21. Sav T, Tokgoz B, Sipahioglu MH, Deveci M, Sari I, Oymak O, Utas C. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail. 2007; 29: 423-426.
22. Schaefer RM, Khasabov NN, Todorov NG, Evenepoel P. The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anaemia. Nephrol Dial Transplant Plus. 2008; 1 (Suppl. 1): ii360 (abstract).
23. Seid MH, Mangione A, Valaoras TG. Safety profile of iron carboxymaltose, a new high dose intravenous iron in patients with iron deficiency anemia. Blood. 2006; 108: 8B.
24. Silverberg DS, Blum M, Agbaria Z et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol. 2001; 55: 212-219.
25. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007; 110: 267-278.